AAVrh74 Platform Technology Designation
This report provides a special focus on the editing technologies shaping the gene therapy field. It highlights the recent platform technology designation awarded to Sarepta Therapeutics for the AAV vector, AAVrh74, and explores its growing role in the AAV gene therapy space.
Using data from Beacon as of June 10th, 2025, this report explores trends in targeted diseases, mechanisms of action, and editing technologies. It also highlights the recent AAVrh74 platform designation – covering its impact, background, and place within the broader AAV delivery landscape.
You May Also Be Interested In…
Learn More About Gene Therapy
- The Most Comprehensive Way to Search the Gene Therapy Development Landscape: Unique search ontologies based on Gene Therapy drug and trial characteristics
- Market Leading Approach to Gene Therapy Preclinical & Clinical Data Curation: Manual curation of key Gene Therapy research and development data points by Gene Therapy research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Gene Therapy company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
